Q1 FY 20 Performance Update

Six spaces which will drive significant growth 2 China We are looking for sustainable high growth in Chinal Many of our US products meet the new Chinese requirements High CAGR in China 24% CAGR 129 100 84 FY17 FY18 Revenues ($ Mn) FY19 What are we going to do in China? Select and launch products that meet local requirements Scale up local manufacturing Scale up partnerships in identified therapy areas 2 We have been present in China for 20 years Established credentials with Regulatory agencies Local Manufacturing experience Familiarity with commercialization in all provinces of China 1- Includes JV Revenue PROPRIETARY

View entire presentation